Clinical Pharmacology & Biopharmaceutics
Open Access

Abstract

The history of Iran pharmaceutical industry returns back to about 70 years ago with a structure mostly based on generic and brand-generic medicines. More than 85 domestic pharmaceutical factories cover more than 96% of country demand and consumption in terms of quantity which generate 65% of the value market size. In 2014, around USD 2.5 Milliard investment in medicine production resulted in more than USD 4.5 Milliard sales value in Iran market. Although Iran pharma industry shows 100% self-reliance and self-sufficiency, it is mostly true in materials used for primary and secondary packaging steps in production lines but not in APIs as a whole (40% of domestic demand), or APIs for vitamins, hormones, and enzymes (70% of local requirement), and high tech medicines. However, the main policy of Iran Ministry of Health and Food and Drug Organization stands on expansion of production facilities either through governmental pharmaceutical holdings or supporting investors from private sector specially in biotic, recombinant medicines, and vaccines. In this respect, GMP revising and upgrading have been instructed to manufacturing premises to meet PIC/s guidelines providing an integrated GMP scheme throughout the country as a requisite for being a member of this convention founded in 1970. Apart from the medicine, there is a significant market for supplements with market size of around USD 1 Milliard and promising consumption trend for nutrition and probiotics. In our study on these market dynamic trends, valuable opportunities were revealed in consistent with and in favor of local and global investments.

Biography

Email: a.behshad.40@gmail.com